Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma HELP
Based on 34,116 articles published since 2008
|||| 19 

These are the 34116 published articles about Melanoma that originated from Worldwide during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
76 Editorial Progress in the diagnosis and therapy of melanoma. 2018

Wiesner, T / Zbyszewski, A. ·Department of Dermatology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. ·Br J Dermatol · Pubmed #29357589.

ABSTRACT: -- No abstract --

77 Editorial Sunscreen and melanoma prevention: evidence and expectations. 2018

Wehner, M R. ·Department of Dermatology, University of Pennsylvania, Philadelphia, PA, U.S.A. ·Br J Dermatol · Pubmed #29357579.

ABSTRACT: -- No abstract --

78 Editorial Malignant Melanoma: How Do We Meet the Needs of Young People and Their Families? 2018

McInally, Wendy. ·a Department of Nursing, School of Health and Social Care , Edinburgh Napier University , Edinburgh , Scotland, United Kingdom. ·Compr Child Adolesc Nurs · Pubmed #29351502.

ABSTRACT: -- No abstract --

79 Editorial Completing the Dissection in Melanoma: Increasing Decision Precision. 2018

Faries, Mark B. ·The Angeles Clinic and Research Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA. mfaries@theangelesclinic.org. ·Ann Surg Oncol · Pubmed #29302819.

ABSTRACT: -- No abstract --

80 Editorial Melanoma Surveillance Strategies: Different Approaches to a Shared Goal. 2018

Shirai, Keisuke / Wong, Sandra L. ·Department of Medicine, The Geisel School of Medicine at Dartmouth and Dartmouth-Hitchcock Medical Center, 1 Medical Center Drive, Lebanon, NH, USA. · Department of Surgery, The Geisel School of Medicine at Dartmouth and Dartmouth-Hitchcock Medical Center, 1 Medical Center Drive, Lebanon, NH, USA. Sandra.L.Wong@hitchcock.org. ·Ann Surg Oncol · Pubmed #29294186.

ABSTRACT: -- No abstract --

81 Editorial SPECT/CT: Looking Beyond Sentinel Lymph Node Identification for Improving Patient Outcomes. 2018

Sibley, Robert / Subramaniam, Rathan M. ·Division of Nuclear Medicine, Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA. · Division of Nuclear Medicine, Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA. rathan.subramaniam@UTsouthwestern.edu. · Harold Simmons Comprehensive Cancer Center, University of Texax Southwestern Medical Center, Dallas, TX, USA. rathan.subramaniam@UTsouthwestern.edu. ·Ann Surg Oncol · Pubmed #29218428.

ABSTRACT: -- No abstract --

82 Editorial The Blood Brain Barrier and BRAF inhibitors: Implications for patients with melanoma brain metastases. 2018

Smalley, Keiran S M / Forsyth, Peter A. ·The Department of Tumor Biology, The Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA; The Department of Cutaneous Oncology, The Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA. Electronic address: keiran.smalley@moffitt.org. · The Department of Neurooncology, The Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA. ·Pharmacol Res · Pubmed #29146209.

ABSTRACT: -- No abstract --

83 Editorial Is the Prognosis of Uveal Melanoma Improving? 2017

Suzuki, Shigenobu. · ·Nippon Ganka Gakkai Zasshi · Pubmed #30074748.

ABSTRACT: -- No abstract --

84 Editorial Dermoscopy - Not just for diagnosis and not just for Dermatologists ! 2017

Sonthalia, S / Errichetti, E. ·Department of Dermatology and Dermatosurgery, The Skin Clinic and Research Centre, Sushant Lok-1, Gurugram-122009, Haryana, India. · Dermatologist and Venereologist, Institute of Dermatology, University Hospital "Santa Maria della Misericordia", Udine, Italy. ·Kathmandu Univ Med J (KUMJ) · Pubmed #29446353.

ABSTRACT: -- No abstract --

85 Editorial Effectiveness of the Mohs and Close Technique in Increasing the Efficiency of a Mohs Micrographic Surgery. 2017

Konda, Sailesh / Francis, Joseph / Patel, Vishal A. · ·J Drugs Dermatol · Pubmed #29240868.

ABSTRACT: Editor's note: JDD welcomes Letters to the Editor that discuss controversy surrounding a recently published article. Letters being considered for publication may be sent to the authors of the original article, who may be given the opportunity to reply. Letters will be published at the discretion of the Editors.

86 Editorial Adjuvant Melanoma Therapy - Head-Spinning Progress. 2017

Schuchter, Lynn M. ·From the University of Pennsylvania Abramson Cancer Center, Philadelphia. ·N Engl J Med · Pubmed #29117487.

ABSTRACT: -- No abstract --

87 Editorial Futures. 2017

Arnheiter, Heinz. · ·Pigment Cell Melanoma Res · Pubmed #29094508.

ABSTRACT: -- No abstract --

88 Editorial Personalized melanoma genomic risk information:perception of shared risk initiates sharing with family. 2017

Robinson, J K / Spring, B. ·Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, U.S.A. · Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, U.S.A. ·Br J Dermatol · Pubmed #29052877.

ABSTRACT: -- No abstract --

89 Editorial Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma. 2017

Carlino, Matteo S / Sandhu, Shahneen. ·Matteo S. Carlino, Westmead and Blacktown Hospitals and University of Sydney, Sydney, New South Wales, Australia · and Shahneen Sandhu, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia. ·J Clin Oncol · Pubmed #29048973.

ABSTRACT: -- No abstract --

90 Editorial Whither melanoma in Australia? 2017

Smithers, B Mark / Dunn, Jeff / Soyer, H Peter. ·University of Queensland, Brisbane, QLD m.smithers@uq.edu.au. · Institute for Resilient Regions, University of Southern Queensland, Toowoomba, QLD. · Princess Alexandra Hospital, Brisbane, QLD. ·Med J Aust · Pubmed #29020902.

ABSTRACT: -- No abstract --

91 Editorial Adjuvant Ipilimumab for Melanoma-The $1.8 Million per Patient Regimen. 2017

Goldstein, Daniel A. ·Davidoff Cancer Center, Rabin Medical Center, Petach Tikvah, Israel · Winship Cancer Institute, Emory University, Atlanta, Georgia ·JAMA Oncol · Pubmed #28983562.

ABSTRACT: -- No abstract --

92 Editorial Clinical and pathologic factors associated with deep transection of biopsies of invasive melanoma. 2017

Woodcock, Jamie L / Eyre, Zachary W / Stoddard, Gregory J / Callis Duffin, Kristina / Bowen, Anneli R. ·Department of Dermatology, University of Utah, Salt Lake City, Utah. Electronic address: jamie.woodcock@hsc.utah.edu. · University of Utah, School of Medicine, Salt Lake City, Utah. · Department of Internal Medicine, University of Utah, Salt Lake City, Utah. · Department of Dermatology, University of Utah, Salt Lake City, Utah. ·J Am Acad Dermatol · Pubmed #28917460.

ABSTRACT: -- No abstract --

93 Editorial The Importance of Early Recognition of Skin Cancer. 2017

Farberg, Aaron S / Rigel, Darrell S. ·Department of Dermatology, Icahn School of Medicine at Mount Sinai, 5 East 98th Street Floor 5, New York, NY 10029, USA. Electronic address: aaron.farberg@gmail.com. · Department of Dermatology, NYU School of Medicine, 35 East 35th Street Suite 208, New York, NY 10016, USA. Electronic address: darrell.rigel@gmail.com. ·Dermatol Clin · Pubmed #28886816.

ABSTRACT: -- No abstract --

94 Editorial "If you want to go far, go together". 2017

Aplin, Andrew E. ·Pigment Cell & Melanoma Research. ·Pigment Cell Melanoma Res · Pubmed #28834183.

ABSTRACT: -- No abstract --

95 Editorial Checkpoint inhibitors in melanoma and early phase development in solid tumors: what's the future? 2017

Ascierto, Paolo A / McArthur, Grant A. ·Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Via Mariano Semmola, 80131, Naples, Italy. paolo.ascierto@gmail.com. · Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. grant.mcarthur@petermac.org. · University of Melbourne, Parkville, VIC, Australia. grant.mcarthur@petermac.org. ·J Transl Med · Pubmed #28789707.

ABSTRACT: Anti-programmed death (PD)-1 and PD-ligand (L)-1 checkpoint inhibitors have revolutionized the therapy of several cancers. Immunotherapy of cancer can offer long-term durable benefit to patients, is active regardless of tumour histology, has a unique immune-related safety profile, and can be used in combination with other cancer treatments. In addition, recent research has shown that immune-based therapy can be used as adjuvant therapy, that outcomes may be influenced by dose, and that clinical activity is observed in patients with brain metastases. Despite our increased understanding of these agents, there are still several important questions that need to be answered. These include strategies to overcome primary and acquired resistance, the influence of mutational status on treatment outcomes, the optimal duration of treatment, and the need to identify novel combination regimens that offer increased anti-tumour potency and/or reduced toxicity. Here we review recent developments in these areas, with particular focus on new data reported at the 2017 ASCO Annual Meeting.

96 Editorial Melanin pigmentation and melanoma. 2017

Picardo, Mauro / Slominski, Andrzej T. ·Cutaneous Physiopathology Laboratory and Metabolomic Center, San Gallicano Dermatological Institute, Rome, Italy. · Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, USA. · Comprehensive Cancer Center Cancer Chemoprevention Program, University of Alabama at Birmingham, Birmingham, AL, USA. · Laboratory Service of the VA Medical Center, Birmingham, AL, USA. ·Exp Dermatol · Pubmed #28699220.

ABSTRACT: -- No abstract --

97 Editorial A Look Inside of the Complex Pathogenesis of B-RAF(V600E)-Driven Cancer. 2017

Caputo, Emilia. ·Institute of Genetics and Biophysics -I.G.B., A. Buzzati-Traverso-, CNR, Via Pietro Castellino, 111, I-80131 Naples, Italy. ·Theranostics · Pubmed #28638488.

ABSTRACT: Cancer is a very complex disease, where cell alterations (i.e. gene mutations, dysregulated signaling pathway(s) and epigenetic modifications) contribute to its development and progression. Elucidating the connections among these cell modifications is a critical challenge, in order to understand the mechanisms which are activated from cancer cells to survive and proliferate. Interesting, Prof. Peng Hou and colleagues, at the First Affiliated Hospital of Xi'an Jiaotong University in China, identified unknown epigenetic mechanisms and their involvement in the tumorigenesis of B-RAF(V600E)-driven cancer.

98 Editorial New strategies in melanoma therapy: can nanoparticles overcome chemoresistance? 2017

Badea, Ildiko. ·College of Pharmacy & Nutrition, University of Saskatchewan, 107 Wiggins Road, Health Sciences Building, Room 3D01.5, Box 3D01-13, Saskatoon, Saskatchewan, S7N 5E5, Canada. ·Nanomedicine (Lond) · Pubmed #28635551.

ABSTRACT: -- No abstract --

99 Editorial Skin cancer mortality in patients with skin of color. 2017

Kaufman, Bridget P / Alexis, Andrew F. ·Mount Sinai St. Luke's and Mount Sinai West, New York, New York, USA. ·Cutis · Pubmed #28632798.

ABSTRACT: -- No abstract --

100 Editorial The Enigma of Regional Lymph Nodes in Melanoma. 2017

Coit, Daniel. ·From the Memorial Sloan Kettering Cancer Center, New York. ·N Engl J Med · Pubmed #28591534.

ABSTRACT: -- No abstract --

Back · Next